In Segment C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, participants will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until eventually sickness progression or the contributors are unable to tolerate the study drugs. There may be larger treatment load for members During this trial in comparison https://aaronq877aku9.westexwiki.com/user